RaoSMLeoGJBernardinL, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology1991; 41(5): 685–691.
2.
PardiniMUccelliAGrafmanJ, et al. Isolated cognitive relapses in multiple sclerosis. J Neurol Neurosurg Psychiat2014; 859: 1035–1037.
3.
KalbRBeierMBenedictRHB, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler J2018; 2413: 1665–1680.
4.
SumowskiJFBenedictREnzingerC, et al. Cognition in multiple sclerosis state of the field and priorities for the future. Neurology2018; 90: 278–288.
5.
TrenovaAGSlavovGSDraganova-FilipovaMN, et al. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. Neurol Res2018; 40(3): 153–159.
6.
KapposLD’SouzaMLechner-ScottJ, et al. On the origin of neurostatus. Mult Scler Relat Disord2015; 4(3): 182–185.
7.
MarrieRACheluneGJMillerDM, et al. Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis. Mult Scler2005; 11(1): 69–75.
8.
BenedictRHBDeLucaJPhillipsG, et al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler2017; 23(5): 721–733.
9.
BenedictRHBMorrowSRodgersJ, et al. Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler J2014; 20(13): 1745–1752.
10.
MorrowSAConwayDFuchsT, et al. Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Mult Scler2021; 27(7): 1077–1087.
11.
CharcotJM.Lectures on the diseases of the nervous system (trans. GSigerson). London: New Sydenham Society, 1877.
